Abstract
The capacity of the immune system to distinguish foreign from self-antigen, and to subsequently eliminate the threat of disease without injuring the host is crucial for survival. It also serves to defend against tumor formation and progression via a process termed cancer immunosurveillance. Innate and adaptive immune cell types and effector molecules collectively function as extrinsic tumorsuppressor mechanisms. However, tumors may escape immunesurveillance through a variety of mechanisms that create a local microenvironment that is unfavorable for effective tumor immunity. Transforming growth factor β (TGF-β) has pleiotropic effects on the immune system, and is recognized as one of the most potent immunosuppressive agents in facilitating oncogenesis. The TGF-β pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the protective host immunity. In this review, we discuss mechanisms through which TGF-β interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies.
Keywords: TGF-β, natural killer, dendritic cells, CD8+ T cells, Th1, Th2, Th17, treg cells, cancer, anti-tumor immunity.
Current Pharmaceutical Design
Title:TGF-Beta: a Master Switch in Tumor Immunity
Volume: 18 Issue: 27
Author(s): Margherita Gigante, Loreto Gesualdo and Elena Ranieri
Affiliation:
Keywords: TGF-β, natural killer, dendritic cells, CD8+ T cells, Th1, Th2, Th17, treg cells, cancer, anti-tumor immunity.
Abstract: The capacity of the immune system to distinguish foreign from self-antigen, and to subsequently eliminate the threat of disease without injuring the host is crucial for survival. It also serves to defend against tumor formation and progression via a process termed cancer immunosurveillance. Innate and adaptive immune cell types and effector molecules collectively function as extrinsic tumorsuppressor mechanisms. However, tumors may escape immunesurveillance through a variety of mechanisms that create a local microenvironment that is unfavorable for effective tumor immunity. Transforming growth factor β (TGF-β) has pleiotropic effects on the immune system, and is recognized as one of the most potent immunosuppressive agents in facilitating oncogenesis. The TGF-β pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the protective host immunity. In this review, we discuss mechanisms through which TGF-β interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies.
Export Options
About this article
Cite this article as:
Gigante Margherita, Gesualdo Loreto and Ranieri Elena, TGF-Beta: a Master Switch in Tumor Immunity, Current Pharmaceutical Design 2012; 18 (27) . https://dx.doi.org/10.2174/138161212802430378
DOI https://dx.doi.org/10.2174/138161212802430378 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets An Efficient Light-weight Network for Fast Reconstruction on MR Images
Current Medical Imaging Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research MMP14 Regulates VEGFR3 Expression on Corneal Epithelial Cells
Protein & Peptide Letters Vector Delivery Methods and Targeting Strategies for Gene Therapy of Brain Tumors
Current Gene Therapy MicroRNAs as Cancer Biomarkers
MicroRNA Thioredoxin, Glutathione and Related Molecules in Tumors of the Nervous System
Current Medicinal Chemistry Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research